Login Register Cart 0
Generic placeholder image

Combinatorial Chemistry & High Throughput Screening

Editor-in-Chief

ISSN (Print): 1386-2073
ISSN (Online): 1875-5402

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

UPLC-MS/MS Assay for Quantification of Wedelolactone and Demethylwedelolactone in Rat Plasma and the Application to a Preclinical Pharmacokinetic Study

Author(s): Bao-e Wang, Lin-tao Zhang, Sheng-bao Yang and Zeng-liang Xu*

Volume 25, Issue 8, 2022

Published on: 26 May, 2021

Page: [1271 - 1277] Pages: 7

DOI: 10.2174/1386207324666210520093517

Price: $65

Abstract

Aims and Objective: Wedelolactone and demethylwedelolactone are the two major coumarin constituents of Herba Ecliptae. The objective of this work was to develop and validate a sensitive, rapid, and robust UPLC-MS/MS method for the simultaneous quantification of wedelolactone and demethylwedelolactone in rat plasma.

Materials and Methods: Wedelolactone and demethylwedelolactone were extracted from rat plasma by protein precipitation with acetonitrile. Electrospray ionization in negative mode and selected reaction monitoring (SRM) were used for wedelolactone and demethylwedelolactone at the transitions m/z 312.8→298.0 and m/z 299.1→270.6, respectively. Chromatographic separation was conducted on a Venusil C18 column (50 mm × 2.1 mm, 5 μm) with isocratic elution of acetonitrile-0.1% formic acid in water (55:45, v/v) at a flow rate of 0.3 mL/min. A linear range was observed over the concentration range of 0.25-100 ng/mL for wedelolactone and demethylwedelolactone.

Results: They reached their maximum plasma concentrations (Cmax, 74.9±13.4 ng/mL for wedelolactone and 41.3±9.57 ng/mL for demethylwedelolactone) at the peak time (Tmax) of 0.633 h and 0.800 h, respectively. The AUC0-t value of wedelolactone (260.8±141.8 ng h/mL) was higher than that of demethylwedelolactone (127.4±52.7 ng h/mL) by approximately 2-fold, whereas the terminal elimination half-life (t1/2) of wedelolactone (2.20±0.59 h) showed the approximately same as that of demethylwedelolactone (2.08±0.69 h).

Conclusion: Based on full validation according to US FDA guidelines, this UPLC-MS/MS method was successfully applied to a pharmacokinetic study in rats.

Keywords: Herba Ecliptae, wedelolactone, demethylwedelolactone, UPLC-MS/MS, rat plasma, pharmacokinetics.

« Previous Next »
[1]
Feng, L.; Zhai, Y.Y.; Xu, J.; Yao, W.F.; Cao, Y.D.; Cheng, F.F.; Bao, B.H.; Zhang, L. A review on traditional uses, phytochemistry and pharmacology of Eclipta prostrata (L.) L. J. Ethnopharmacol., 2019, 245(12), 112109.
[http://dx.doi.org/10.1016/j.jep.2019.112109] [PMID: 31395303]
[2]
Li, N.; Shi, S.; Yang, F.; Wang, H.; Su, J.; Huang, F.; Wu, H.; Wu, X.; Wang, S. A polysaccharide from Eclipta prostrata alleviates experimental autoimmune encephalomyelitis through inhibiting Th17 cells. Carbohydr. Polym., 2018, 201(12), 608-614.
[http://dx.doi.org/10.1016/j.carbpol.2018.08.113] [PMID: 30241860]
[3]
Chinese Pharmacopoeia Commission Pharmacopoeia of the People’s Republic of China; China Medical Science Publisher: Beijing, 2015, Vol. 1, pp. 374-375.
[4]
Thirumalai, T.; David, E.; Viviyan, T.S.; Elumalai, E.K. Restorative effect of Eclipta alba in CCl4 induced hepatotoxicity in male albino rats. Asian Pac. J. Trop. Med., 2011, 1(4), 304-307.
[http://dx.doi.org/10.1016/S2222-1808(11)60072-8]
[5]
Kim, D.S.; Kim, S.H.; Kee, J.Y.; Han, Y.H.; Park, J.; Mun, J.G.; Joo, M.J.; Jeon, Y.D.; Kim, S.J.; Park, S.H.; Park, S.J.; Um, J.Y.; Hong, S.H. Eclipta prostrata improves DSS-induced colitis through regulation of inflammatory response in intestinal epithelial cells. Am. J. Chin. Med., 2017, 45(5), 1047-1060.
[http://dx.doi.org/10.1142/S0192415X17500562] [PMID: 28659027]
[6]
Jung, W.Y.; Kim, H.; Park, H.J.; Jeon, S.J.; Park, H.J.; Choi, H.J.; Kim, N.J.; Jang, D.S.; Kim, D.H.; Ryu, J.H. The ethanolic extract of the Eclipta prostrata L. ameliorates the cognitive impairment in mice induced by scopolamine. J. Ethnopharmacol., 2016, 190(8), 165-173.
[http://dx.doi.org/10.1016/j.jep.2016.06.010] [PMID: 27267831]
[7]
Ho, Y.S.; So, K.F.; Chang, R.C. Anti-aging herbal medicine--how and why can they be used in aging-associated neurodegenerative diseases? Ageing Res. Rev., 2010, 9(3), 354-362.
[http://dx.doi.org/10.1016/j.arr.2009.10.001] [PMID: 19833234]
[8]
Kim, D.I.; Lee, S.H.; Hong, J.H.; Lillehoj, H.S.; Park, H.J.; Rhie, S.G.; Lee, G.S. The butanol fraction of Eclipta prostrata (Linn) increases the formation of brain acetylcholine and decreases oxidative stress in the brain and serum of cesarean-derived rats. Nutr. Res., 2010, 30(8), 579-584.
[http://dx.doi.org/10.1016/j.nutres.2010.08.001] [PMID: 20851313]
[9]
Li, X.; Wang, T.; Liu, J.; Liu, Y.; Zhang, J.; Lin, J. Effect and mechanism of wedelolactone as antioxidant-coumestan on OH-treated mesenchymal stem cells. Arab. J. Chem., 2020, 13(1), 184-192.
[http://dx.doi.org/10.1016/j.arabjc.2017.03.008]
[10]
Lu, Y.; Hu, D.; Ma, S.; Zhao, X.; Wang, S.; Wei, G.; Wang, X.; Wen, A.; Wang, J. Protective effect of wedelolactone against CCl4-induced acute liver injury in mice. Int. Immunopharmacol., 2016, 34(5), 44-52.
[http://dx.doi.org/10.1016/j.intimp.2016.02.003] [PMID: 26921731]
[11]
Prakash, T.; Rao, N.R.; Swamy, A.H. Neuropharmacological studies on Wedelia calendulacea Less stem extract. Phytomedicine, 2008, 15(11), 959-970.
[http://dx.doi.org/10.1016/j.phymed.2008.05.005] [PMID: 18603418]
[12]
Lee, Y.J.; Lin, W.L.; Chen, N.F.; Chuang, S.K.; Tseng, T.H. Demethylwedelolactone derivatives inhibit invasive growth in vitro and lung metastasis of MDA-MB-231 breast cancer cells in nude mice. Eur. J. Med. Chem., 2012, 56(10), 361-367.
[http://dx.doi.org/10.1016/j.ejmech.2012.07.041] [PMID: 22926226]
[13]
S, M.; T, P.; Goli, D. Effect of wedelolactone and gallic acid on quinolinic acid-induced neurotoxicity and impaired motor function: significance to sporadic amyotrophic lateral sclerosis. Neurotoxicology, 2018, 68(9), 1-12.
[http://dx.doi.org/10.1016/j.neuro.2018.06.015] [PMID: 29981346]
[14]
Chen, Q.; Wu, X.; Gao, X.; Song, H.; Zhu, X. Development and validation of an ultra-performance liquid chromatography method for the determination of wedelolactone in rat plasma and its application in a pharmacokinetic study. Molecules, 2019, 24(4), 762.
[http://dx.doi.org/10.3390/molecules24040762] [PMID: 30791539]
[15]
Yin, J.; Lu, G.; Jiang, J. Determination of the specnuezhenide and wedelolactone in Erzhi Formula and their pharmacokinetics in rats by HPLC-MS/MS. Chin. J. Trad. Chin. Med. Pharm., 2018, 33(10), 4610-4614.
[16]
Du, G.; Fu, L.; Jia, J.; Pang, X.; Yu, H.; Zhang, Y.; Fan, G.; Gao, X.; Han, L. Validated UPLC-MS/MS method for quantification of seven compounds in rat plasma and tissues: Application to pharmacokinetic and tissue distribution studies in rats after oral administration of extract of Eclipta prostrata L. Biomed. Chromatogr., 2018, 32(6), e4191.
[http://dx.doi.org/10.1002/bmc.4191] [PMID: 29349861]
[17]
FDA 2018. in: Available at: www.fda.gov/media/70858/download
[18]
EMEA 2011. in: Available at: www.ema.europa.eu/docs/en_GB/document library/Scientif ic guideline/2011/08/WC500109686.pdf
[19]
Deng, Z.; Liu, Q.; He, J.; Zhang, S.; Zhou, W. Validation of an UHPLC-MS/MS method for the determination of glaucocalyxin A, a novel potent negative Akt regulator in rat plasma, lung and brain tissues: application to a pharmacokinetic study. J. Chromatogr. Sci., 2020, 58(3), 234-240.
[20]
Matuszewski, B.K.; Constanzer, M.L.; Chavez-Eng, C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem., 2003, 75(13), 3019-3030.
[http://dx.doi.org/10.1021/ac020361s] [PMID: 12964746]
[21]
O’Halloran, S.J.; Wong, A.; Joyce, D.A. A liquid chromatography-tandem mass spectrometry method for quantifying amisulpride in human plasma and breast milk, applied to measuring drug transfer to a fully breast-fed neonate. Ther. Drug Monit., 2016, 38(4), 493-498.
[http://dx.doi.org/10.1097/FTD.0000000000000300] [PMID: 27027463]
[22]
Matta, M.K.; Pilli, N.R.; Rao, J.V.L.N.S. Bioanalysis of raltegravir, an integrase inhibitor in human plasma by novel SPE-ESI-LC-MS/MS method and its pharmacokinetic application. Am. J. PharmaTech Res., 2013, 3, 575-586.
[23]
S, I.P.; Varanasi, M.B.; Mohammed, I. Bioanalysis of monomethyl fumarate in human plasma by a sensitive and rapid LC-MS/MS method and its pharmacokinetic application. J. Pharm. Biomed. Anal., 2017, 146, 109-116.
[http://dx.doi.org/10.1016/j.jpba.2017.08.015] [PMID: 28873360]

Rights & Permissions Print Cite
Article Metrics
42
1
© 2024 Bentham Science Publishers | Privacy Policy